ArticleFrontiers in public health2026
Cost-effectiveness of tremelimumab plus durvalumab versus sorafenib for unresectable hepatocellular carcinoma in China: an economic evaluation based on five-year overall survival data from the HIMALAYA trial.
Rui Feng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.